Author: Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Jarrard D, Kibel AS, Kim S, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Wake R, Yuh B
Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
Type of cancer: Genitourinary, Prostate
Patient population: Adult
Location: International
This is a clinical practice guideline developed for adult men who have elected to participate in an early prostate cancer detection program. The guideline provides a set of sequential recommendations detailing screening and evaluation strategies for maximizing the detection of prostate cancer that is effectively treatable and that, if left undetected, represents a risk to the patient. Several techniques designed to improve the identification of significant cancer, while avoiding the detection of indolent disease, are highlighted, including imaging, biomarker testing, and biopsy.
AGREE II - Quality of Reporting Assessment:
Scope and purpose: 72.2%
Applicability: 29.2%
Stakeholder involvement: 69.4%
Editorial independence: 79.2%
Rigour: 66.7%
Clarity presentation: 75%
